Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.62 |
| ▸ | MAOB | P27338 | 6/20 | 0.62 |
| ▸ | BACE1 | P56817 | 3/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970523 | 1.00 | APP (0.62) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL27414819 | 0.95 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL15970480 | 0.92 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL14248288 | 0.92 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL27414810 | 0.89 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL30730012 | 0.89 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL27160315 | 0.89 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL11650628 | 0.89 | BACE1 (0.60) | APPMAOBBACE1PTPN1KMT2A | |
| SCHEMBL29761488 | 0.82 | APP (0.76) | APPMAOBBACE1PTPN1 | |
| SCHEMBL12539779 | 0.81 | BACE1 (0.56) | APPMAOBBACE1PTPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464016-B2 | Catechol derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140243424-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2720689-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | Edison Pharmaceuticals, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174286-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243424-A1 | CATECHOL DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | OPA1, PC, PCK2 | APP 638/4885MAOB 209/4885BACE1 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.